Want to see ANAB full AI Analyst Report?
AnaptysBio (ANAB) AI Stock Analysis
AnaptysBio
(NASDAQ:ANAB)
The score is driven by a meaningful financial turnaround (strong TTM profitability and improved cash flow) but tempered by a weakened balance-sheet cushion (very low equity) and only modest/weak technical momentum. Valuation helps, with a low P/E supporting the stock despite the sustainability and volatility risks implied by cash conversion and revenue concentration.
AnaptysBio Key Performance Indicators (KPIs)
Operating Income by SegmentHow much profit or loss each business segment generates at the operating level. For a clinical-stage company like AnaptysBio, negative operating income typically reflects R&D burn concentrated in research units, while any positive segments point to collaboration or licensing activities that help offset costs. Reveals cost structure, cash runway pressure, and whether resources are being allocated toward development or commercialization.
Biopharma is the clear operating loss driver, reflecting heavy ongoing R&D investment, while Royalty Management generates positive operating income that meaningfully offsets some of that burn. That split signals a company increasingly reliant on monetizing IP/licensing to fund development; sustaining or growing royalty receipts — or cutting Biopharma spend — will be the critical determinants of cash runway and near‑term valuation risk for investors.
The FlyAnaptysBio (ANAB) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $1.43B
- Dividend Yield
- ―
- Average Volume (3M)
- 482.30K
- Price to Earnings (P/E)
- 7.1
- Beta (1Y)
- 0.81
- Revenue Growth
- 92.92%
- EPS Growth
- ―
- Country
- US
- Employees
- 104
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
AnaptysBio Business Overview & Revenue Model
Company Description
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company’s products include Rosnilimab, a selective pathogenic T cell deplete wh...
How the Company Makes Money
AnaptysBio primarily generates revenue through collaboration and licensing arrangements rather than product sales, as it is a clinical-stage company with no marketed products. Its revenue model typically includes (when present under specific agreemen...
AnaptysBio Financial Statement Overview
Summary
Income statement strength is the key positive (Score 72): TTM shows a sharp swing to high profitability and rapid revenue growth. Cash flow is improved but less supportive than earnings (Score 61), with operating cash flow a small fraction of net income, implying lumpiness/less cash-backed profits. Balance sheet is the main risk (Score 46) as equity has compressed materially, reducing cushion and making leverage metrics look less comfortable.
Income Statement
72PositiveBalance Sheet
46NeutralCash Flow
61Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 237.61M | 234.60M | 91.28M | 17.16M | 10.29M | 63.17M |
| Gross Profit | 316.29M | 232.18M | -72.56M | -115.13M | -78.51M | -35.32M |
| EBITDA | 91.91M | 69.25M | -92.74M | -154.70M | -105.26M | -55.71M |
| Net Income | 195.72M | -13.23M | -145.23M | -163.62M | -128.72M | -57.80M |
Balance Sheet | ||||||
| Total Assets | 316.98M | 364.39M | 483.83M | 452.39M | 610.38M | 643.07M |
| Cash, Cash Equivalents and Short-Term Investments | 164.14M | 311.64M | 385.37M | 390.90M | 441.24M | 548.10M |
| Total Debt | 269.59M | 14.11M | 369.46M | 17.81M | 19.45M | 20.95M |
| Total Liabilities | 306.40M | 327.19M | 412.97M | 364.29M | 348.28M | 286.64M |
| Stockholders Equity | 10.59M | 37.21M | 70.87M | 88.10M | 262.10M | 356.43M |
Cash Flow | ||||||
| Free Cash Flow | 18.07M | 19.61M | -135.69M | -121.61M | -73.95M | -47.29M |
| Operating Cash Flow | 18.08M | 19.70M | -135.34M | -120.80M | -73.59M | -45.92M |
| Investing Cash Flow | 219.33M | 228.03M | 95.40M | 144.75M | -394.85M | 38.84M |
| Financing Cash Flow | -147.88M | -132.61M | 127.05M | -59.30M | 44.02M | 252.30M |
AnaptysBio Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANAB, the sentiment is Negative. The current price of 47.73 is above the 20-day moving average (MA) of 47.57, below the 50-day MA of 51.33, and below the 200-day MA of 50.57, indicating a neutral trend. The MACD of -0.69 indicates Negative momentum. The RSI at 45.73 is Neutral, neither overbought nor oversold. The STOCH value of 33.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ANAB.
AnaptysBio Risk Analysis
AnaptysBio disclosed 49 risk factors in its most recent earnings report. AnaptysBio reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksAnaptysBio Peers Comparison
Overall Rating
- ANAB63Neutral
ZYME59Neutral
CRVS54Neutral
XNCR47.4Neutral
CGEM45Neutral
CTMX34Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ANAB | 63Neutral | $1.40B | 7.07 | 2515.23% | ― | 92.92% | ― |
| ZYME | 59Neutral | $2.06B | -14.91 | -72.07% | ― | -69.78% | -106.07% |
| CRVS | 54Neutral | $815.97M | -15.36 | -36.15% | ― | ― | 8.14% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| XNCR | 47Neutral | $2.21B | -14.12 | -28.66% | ― | -28.56% | 10.25% |
| CGEM | 45Neutral | $960.82M | -4.67 | -52.89% | ― | ― | 3.56% |
| CTMX | 34Underperform | $485.92M | -4.84 | -38.46% | ― | -87.03% | -179.91% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ANAB | AnaptysBio | 47.73 | 22.27 | 87.46% | |
| XNCR | Xencor Inc. | 30.64 | 16.64 | 118.86% | |
| CTMX | CytomX Therapeutics Inc. | 2.18 | -2.01 | -47.97% | |
| CRVS | Corvus Pharmaceuticals Inc. | 9.83 | 2.01 | 25.70% | |
| ZYME | Zymeworks | 30.13 | 12.23 | 68.32% | |
| CGEM | Cullinan Therapeutics Inc | 15.75 | 8.40 | 114.29% |
AnaptysBio Corporate Events
AnaptysBio Shareholders Back Board, Governance and Incentives
PositiveOn August 11, 2026, AnaptysBio, Inc. held its 2026 Annual Meeting of Stockholders, where shareholders elected Class III directors Hollings Renton and John P. Schmid to three-year terms extending to the 2029 Annual Meeting. The voting results showed s...
AnaptysBio Enters Key Post-Trial Phase in Tesaro Dispute
NeutralIn November 2025, AnaptysBio filed a Verified Complaint in the Delaware Court of Chancery alleging that Tesaro materially breached their Collaboration and Exclusive License Agreement and that GlaxoSmithKline, Tesaro’s corporate parent, tortious...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 23, 2026